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Abstract: The mainstay in the treatment of ocular inflammation, either post-surgical or 
endogenous, is the use of steroids.  While these agents effectively address inflammation, they are 
not without their risks, including ocular hypertension and acceleration of cataract formation. The 
most notorious culprits are the strong steroids, such as prednisolone acetate and betamethasone. 
This review aims to cover the biochemistry and drug development of difluprednate, a novel 
synthetic strong steroid emulsion.  In vivo pharmacokinetics as well as ocular distribution and 
metabolism are discussed, followed by a comprehensive summary of phase I, II, and III clinical 
trials evaluating safety and efficacy in patients suffering from postoperative inflammation or 
anterior uveitis. The objective is to provide an increased familiarity with this newly approved 
medication as a welcome addition to the ophthalmologist’s armamentarium.
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Introduction
Surgical technique in all fields of ophthalmology has evolved considerably over the 
years, from the transition to clear corneal incisions by anterior segment surgeons to the 
adoption of small-gauge minimally invasive pars plana vitrectomies by vitreoretinal 
specialists. Despite such technical advances, however, surgical manipulation of ante-
rior segment structures triggers the release of arachidonic acid from cell membranes, 
leading to the production of prostaglandins and leukotrienes. These inflammatory 
mediators, in turn, lead to cellular reaction and protein leakage. Although often self-
limited, untreated inflammation can lead to complications such as pain/discomfort, 
photophobia, corneal edema, synechiae, glaucoma, and cystoid macular edema.1,2
In the immediate postoperative period, topical corticosteroids are employed to sup-
press the production of inflammatory mediators, offering local treatment without the 
risk of systemic adverse effects. By inhibiting the release of arachidonic acid from cell 
membrane phospholipids, corticosteroids prevent the formation of both leukotrienes 
and prostaglandins, disrupting the inflammatory cascade.3 These agents are continued 
until the anterior chamber (AC) reaction has resolved and the blood–aqueous barrier 
has been reestablished.4
Just as ophthalmologists have enjoyed advances in surgical technique and 
technology, patient expectations of their results have grown proportionately. Currently, 
the most widely prescribed strong topical corticosteroid in the US is prednisolone 
acetate 1%. While it controls inflammation effectively, it has not been shown to con-
sistently address postoperative pain and discomfort in a large clinical trial.5 In June Clinical Ophthalmology 2009:3 382
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2008 difluprednate ophthalmic emulsion 0.05% (Durezol™; 
Sirion Therapeutics, Tampa, FL) was approved by the US 
Food and Drug Administration (FDA) for the treatment of 
inflammation and pain associated with ocular surgery – the 
first strong ophthalmic steroid approved by the FDA since 
1973. Difluprednate is the first ophthalmic steroid developed 
in the past 35 years with high potency, a favorable safety 
profile, and the ability to reduce postoperative pain.
Review of pharmacology, 
formulation, pharmacokinetics, 
and in vivo analyses of difluprednate
Pharmacology and drug development
Difluprednate (difluoroprednisolone butyrate acetate, or 
DFBA) is a synthetic difluorinated prednisolone deriva-
tive (Figure 1). Originally developed for dermatologic 
applications, the molecule derives its potency from fluorina-
tion at the C6 and C9 positions.6 Its anti-inflammatory activity 
is further augmented by replacing the 17-hydroxyl group 
with butyrate, while its lipophilicity – and hence corneal 
penetration – is enhanced by substituting the 21-hydroxyl 
group with acetate.7 Given the paucity of strong ophthalmic 
steroids available, difluprednate was formulated as a topical 
ophthalmic preparation.
Developing new ophthalmic treatments, however, 
involves numerous challenges. Many drugs are poorly soluble 
in water, for example. While this difficulty can be overcome 
by using surfactants, organic solvents, or a vehicle with pH 
outside physiological range, 8–11 such modifications can lead 
to ocular irritation and limit use in clinical practice.
Ophthalmic suspensions (such as prednisolone acetate) 
can have potential problems such as flocculation, caking, and 
poor redispersibility, all of which can lead to dosing errors 
during administration.12,13 Dose uniformity also depends on 
drug homogeneity, and suspensions have a large range of par-
ticle size, which can affect bioavailability. In addition, they 
must be shaken to suspend the medicine in the aqeous phase, 
otherwise the active drug settles at the bottom of the bottle 
thereby altering the dose delivered. Yet another obstacle is 
that particle variance precludes ophthalmic suspensions from 
undergoing a filtration technique of sterilization.7
One elegant solution to these problems is to create an 
oil-in-water lipid emulsion. This allows drugs that are poorly 
water soluble to dissolve in the oil phase (which does not 
have uniformity problems), undergo sterile filtration, and 
provide better ocular bioavailability.7 As mentioned above, 
lipid emulsions also require the addition of surfactants, 
and both high concentrations of these agents and the use 
of ionic varieties can lead to ocular toxicity.14 Selecting the 
appropriate oil and its concentration is also critical, since an 
emulsion’s thermodynamic stability changes with the propor-
tions of drug, surfactant, and oil; high oil concentrations, for 
example, can lead to blurred vision.15,16
The difluprednate emulsion formulation began by 
suspending DFBA in a variety of oils (castor, cottonseed, 
medium-chain fatty acid triglyceride, oleic, olive, peanut, 
and soybean).7 As castor oil showed the highest solubility, 
it was selected as the lipid phase. Next, various concentra-
tions of polysorbate 80, a nonionic emulsifying surfactant 
with a good safety profile for ophthalmic use, were added to 
determine the optimal proportion of drug, oil, and surfactant 
to avoid blurred vision and ocular surface toxicity. After 
several experiments, the final proportions were selected, with 
a resulting combination that was thermodynamically stable 
across a variety of storage conditions.
Pharmacokinetics
Once instilled, difluprednate emulsion is rapidly deacety-
lated in the aqueous humor to difluoroprednisolone butyrate 
(DFB), the drug’s active metabolite, which has a similar 
corticosteroid activity profile.17 Endogenous tissue esterases 
then metabolize DFB to the inert metabolite hydroxyfluoro-
prednisolone butyrate (HFB), which limits systemic exposure 
to the active compound.18
Due to low drug concentrations and the possibility of 
contaminant proteins in aqueous humor, Yasueda et al19 
used a combination of semi-micro high-performance liquid 
chromatography (HPLC) and column switching to detect in 
vivo ocular absorption of DFBA in a rabbit model. Using 
various concentrations of DFBA emulsion, the group found 
that DFBA could not be detected in aqueous humor samples 
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indicating that the DFBA acetyl group was hydrolyzed 
quickly. They also reported that further DFB hydrolysis does 
not occur within the first hour after drop instillation.
In comparing the in vivo penetration of 0.05% diflupred-
nate emulsion to suspension, Yamaguchi et al7 found that 
within 30 minutes of instillation the emulsion had a 7.4-fold-
higher corneal DFB concentration than did the suspension. 
The emulsion also showed a 5.7- and 3.1-fold higher aqueous 
humor concentration at 1 and 3 hours, respectively, compared 
with suspension.
Ocular distribution and metabolism
To further evaluate the absorption, distribution, and metabo-
lism of 0.05% DFBA emulsion, Tajika et al18 instilled a single 
drop of medication in both eyes of albino rabbits, and mea-
sured the concentrations of DFBA and DFB in ocular tissues 
and blood at several time points using the HPLC method. 
Because of the rapid deacetylation of DFBA to DFB, DFBA 
concentrations were undetectable in nearly all tissue samples, 
while DFB was found to accumulate throughout the anterior 
segment structures. DFB levels in the posterior segment and 
blood were undetectable at all time points.
In a separate study examining DFBA excretion, radio-
labeled difluprednate was instilled in the right eyes of pig-
mented rabbits.18 After a single dose, radioactivity was detected 
in both anterior and posterior ocular structures, but not in the 
blood. At 24 hours postinstillation, 78.5% of radioactivity had 
been excreted, and 99.5% had been eliminated by 168 hours 
(7 days). Radioactivity levels did not increase markedly with 
an increased number of doses. Following 28 doses given over 
7 days, concentrations distributed in the anterior segment 
were 1.5 times higher when compared to a single dose. There 
remained little accumulation in the blood, however, highlight-
ing the rapid metabolism of DFB into inert products.
Preclinical in vivo analyses
Investigating the ocular and systemic safety of difluprednate 
emulsion, Sakaki et al20 compared the effects of difluprednate 
0.01% to 0.05% in rabbits as well as difluprednate 0.05% to 
betamethasone sodium phosphate 0.1% in beagles. Betameth-
asone is a strong corticosteroid widely used in Europe, Canada, 
and Japan to treat ocular inflammation, and, on a molecular 
basis, is six times more potent than prednisolone.3
After four-times-daily (qid) dosing for 1 month, exten-
sive evaluations were performed, including ophthalmic 
examination, hematology, blood chemistries, and organ 
histopathology. Physiological changes in the diflupred-
nate group were slightly less severe than those seen in the 
betamethasone group, suggesting quick metabolism and 
therefore weak systemic exposure to DFBA. Overall, no 
significant ocular or systemic toxicities uncharacteristic of 
steroid use were noted in any group.
In a rabbit model, Inoue et al21 tested the effect of for-
mulation and particle size on ocular bioavailability. Fifty 
microliters (µL) of difluprednate 0.05% emulsion was instilled 
in the right eyes, while 50 µL of the suspension form was 
administered to the left eyes. Using liquid chromatography 
tandem mass spectrometry, they found aqueous humor con-
centrations of difluprednate emulsion 0.05% to be higher 
at all time points following instillation than the suspension 
formulation. Further, the emulsion gave a 1.4-fold higher 
maximal concentration, providing 40% more bioavailability. 
Instilling emulsions with particle sizes between 90.3 and 129.3 
nanometers (nm) (standard particle size 110 nm) gave similar 
aqueous concentrations at 1 hour post-instillation, indicating 
that difluprednate transfer was not affected by particle size.
A rabbit model was created both to assess the dose response 
of  DFBA in postoperative inflammation and compare the 
effect of difluprednate 0.05% to betamethasone 0.1%.22 
A laser flare cell meter was used to quantify AC protein leak-
age at several time points following surgical paracentesis and 
instillation of difluprednate 0.002%, 0.01%, or 0.05%; beta-
methasone 0.1%, or normal saline. Difluprednate concentra-
tions 0.01% showed a statistically significant inhibition of 
inflammation compared to saline, with the anti-inflammatory 
response proceeding in a dose-dependent manner (P  0.01 
for difluprednate 0.01%; P  0.001 for difluprednate 0.05%). 
Difluprednate 0.05% was also found to have an inhibitory 
effect equivalent to that of betamethasone 0.1% (P  0.001 
for each drug when compared to saline, no significant differ-
ence when compared to each other using the t test).
To evaluate anti-inflammatory effects, difluprednate 0.002%, 
0.01%, and 0.05% were compared to betamethasone 0.1% in 
experimental melanin protein-induced uveitis in rats, bovine 
serum albumin–induced uveitis in rabbits, and endotoxin-
induced uveits in rats.23 Difluprednate suppressed uveitis in all 
three models in a dose-dependent manner, and difluprednate 
0.05% showed statistically superior anti-inflammatory activity 
compared to betamethasone 0.1% (P  0.01 in all models).
Review of clinical studies 
and randomized trials
Early efficacy and safety studies
In 1999 a phase I study assessed the safety and tolerability of 
3 concentrations of  difluprednate ophthalmic emulsion given Clinical Ophthalmology 2009:3 384
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as a single instillation to otherwise healthy volunteers.24 In 
this randomized placebo-controlled single-masked trial, 
18 patients were assigned in a 1:1:1 ratio to receive a single 
instillation of vehicle in one eye, and either difluprednate 
0.002%, 0.01%, or 0.05% in the fellow eye. Ocular 
examinations were conducted at several time points up to 
24 hours post-installation, along with assessments of sev-
eral ocular surface parameters and ERG testing. Subjective 
symptoms and tolerability were rated using a questionnaire. 
At the end of the 24-hour period, medical and ophthalmologic 
examinations were performed along with extensive blood 
work. All adverse effects (AEs) were mild, transient, and not 
necessarily related to drop instillation, demonstrating that a 
single installation of difluprednate at any of the concentra-
tions tested was safe and well tolerated.
A second phase I study evaluated the safety, tolerability, 
and pharmacokinetics of 2 difluprednate concentrations 
administered qid for 7 days in healthy male volunteers.25 In 
this placebo-controlled, double-masked study, 12 subjects 
were assigned in a 1:1 ratio to receive 2 drops of placebo in 
1 eye and 2 drops of either difluprednate 0.01% or 0.05% in 
the contralateral eye. Ophthalmic examinations, symptom 
questionnaires, physical examinations, and blood work were 
all conducted in a manner similar to that described above. 
Drug pharmacokinetics were determined by measuring serum 
drug concentration at several time points during the week. 
The results of this study demonstrated that topical diflupred-
nate at either concentration was well tolerated and exhibited 
little systemic effect. No difluprednate was detected in any 
blood sample, with a detection limit of 50 ng/mL. Once 
again, AEs were mild in intensity and transient in nature. 
There were three instances of elevated intraocular pressure 
(IOP), but none exceeded the normal range.
Next, a phase 2A study assessed the efficacy and safety 
of difluprednate emulsion 0.002% or 0.05% administered 
qid for 7 days following cataract surgery.26 Because of strict 
eligibility requirements, this randomized, double-masked, 
parallel-group comparative study enrolled only 6 patients, 
precluding a direct comparison of the two concentrations. 
Efficacy was determined by quantifying AC cells and flare, 
while safety was assessed by ophthalmic examination, 
a subjective evaluation, and blood work. The results of this 
study indicated that both concentrations of difluprednate were 
effective and well tolerated for the treatment of postoperative 
inflammation. All AEs were mild or moderate in severity and 
transient in nature.
A multicenter randomized parallel-group active-control 
phase 2B clinical study compared the efficacy and safety of 
difluprednate 0.05% to betamethasone 0.1% for the treatment 
of postoperative inflammation.27 Twenty-four patients with 
AC cell scores 2 (10 to 20 cells per high-powered field), 
were randomized to receive either difluprednate 0.05% or 
betamethasone 0.1% qid for 14 days. Efficacy and safety 
were measured in a manner similar to that described above. 
There were no statistically significant differences between 
the treatment groups in mean AC cell count, mean AC flare, 
or mean total symptoms on days 3, 7, or 14. In both arms, 
most measures were significantly improved from baseline 
on days 7 and 14. There were no serious AEs during the 
study period, and only one patient in the difluprednate 
group experienced mild IOP elevation, which resolved 
following treatment with a topical antiglaucoma medica-
tion. This study showed that treatment with difluprednate 
0.05% was at least as effective as betamethasone 0.1% in 
reducing postoperative inflammation, and that its safety 
profile was acceptable.
Larger randomized clinical 
and comparative trials
Postoperative inflammation
A phase 3 multicenter randomized double-masked parallel-
group comparative noninferiority trial conducted in Japan 
assessed the safety and efficacy of 0.05% difluprednate 
to 0.1% betamethasone for the treatment of postoperative 
inflammation following cataract or vitreous surgery.28 One 
hundred eighty-two patients with AC cell scores of 2 or 
higher (10+ cells per high-powered field) were randomized 
to receive one of the medications qid for 14 days. The 
primary endpoint used to compare the two treatments was 
change from baseline in AC cell score on day 14. Secondary 
endpoints included changes in cell score at interim time 
points, as well as changes from baseline in AC flare, total 
signs, and total symptom score.
At the completion of the study period, postoperative 
inflammation was similarly reduced in both groups, verifying 
the study’s noninferiority hypothesis (P  0.01). Analysis of 
secondary endpoints revealed no differences between diflu-
prednate and betamethasone in either AC flare or total sign 
score – except for day 7 when the difluprednate arm showed 
a statistically significant improvement in total sign score, 
including hyperemia, chemosis, and keratic precipitates. The 
difluprednate group also showed a statistically significant 
improvement compared to the betamethasone group in sub-
jective symptoms, including pain, photophobia, foreign body 
sensation, and blurred vision at all time points after the initia-
tion of therapy. A few patients in each group experienced Clinical Ophthalmology 2009:3 385
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elevated IOP, all of which resolved spontaneously or with 
the addition of a topical agent. This study verified that diflu-
prednate was at least as effective as betamethasone in treat-
ing postoperative inflammation, and that it had a favorable 
safety profile.
Two identical Phase 3 multicenter randomized repeated-
dose double-masked parallel-group placebo-controlled trials 
were conducted at 26 sites in the United States to assess the 
safety and efficacy of difluprednate emulsion. Four hundred 
thirty-eight patients with AC cell scores of grade 2 or 
higher (10 cells per high-powered field) following ocular 
surgery29 were randomized to one of four treatment arms: 
difluprednate twice daily (bid) (n = 111), difluprednate qid 
(n = 107), or placebo dosed two or four times daily (n = 110 
each). Patients were instructed to use the medication at the 
assigned frequency; if their inflammation had responded satis-
factorily at day 15, they entered a tapering schedule. Outcome 
measures were AC cell grade, AC flare score, and a quantita-
tive evaluation of pain, discomfort, and photophobia.
As early as day 3 there was a mean decrease in AC cell 
grade, from an initial baseline of approximately 2.4, to 1.0 
in the difluprednate bid group and 0.8 in the difluprednate 
qid group, compared to 0.4 in the placebo groups. This 
correlated with an 87% reduction in AC cell count in the 
difluprednate groups versus only a 30% reduction in the pla-
cebo groups. These responses were sustained throughout the 
study. The proportion of patients achieving an AC cell grade 
of 0 (defined as 1 cell per high-powered field) rose over 
time, reaching 77% in the difluprednate twice-daily group and 
81% in the difluprednate four-times-daily group, compared 
to 25% in the placebo group by day 29 (P  0.0001).
The proportion of patients with a clinical response (defined 
as 5 AC cells and no flare) was noted as early as day 3, with 
significant differences observed by day 8. At 1 week after 
surgery, 46.4% of patients in the difluprednate bid (twice daily 
dosing) group and 42.1% in the difluprednate qid group had 
achieved a clinical response (Figure 2), compared with 18.9% 
in the placebo group (P  0.0001). This trend continued to 
increase, and by day 29, 79.1% and 82.2% of patients in the 
difluprednate bid and qid groups, respectively, had a clinical 
response versus 39.4% in the placebo group (P  0.0001).
Difluprednate also reduced pain as early as day 3, with 
38.2% of the bid patients (P = 0.0125) and 45.3% of the 
four-times-daily patients (P  0.0001) claiming to be pain 
and discomfort free, versus 24.8% of patients in the pla-
cebo group. On day 3, patients randomized to difluprednate 
had a substantial reduction in photophobia from baseline 
(P = 0.0041 in the bid group, P  0.0001 in the qid group), 
while scores for placebo-treated patients worsened. The 
trends established by the difluprednate groups continued 
throughout the study.
The mean IOP remained within the normal range in all 
treatment groups, with only 3 patients in each difluprednate 
group and 2 patients in the placebo groups experiencing a 
clinically significant IOP rise (defined as 10 mm Hg from 
baseline and 21 mm Hg overall). Elevated IOP was effec-
tively controlled with topical medication. No serious ocular 
AEs were reported in any treatment group, while systemic 
events were typical for the geriatric study population, giv-
ing no indication that difluprednate had caused target organ 
toxicity.
This multicenter randomized trial once again demonstated 
the safety and efficacy of difluprednate emulsion. More 
important, however, was the finding that the signs and 
symptoms seen following ocular surgery were effectively 
treated with twice-daily dosing. Less frequent dosing may 
engender better patient compliance and reduce total steroid 
exposure.
Anterior uveitis
In a phase 3 noninferiority study conducted in Japan, diflu-
prednate 0.05% was compared to betamethasone 0.1% in 
patients with endogenous anterior uveitis.30 One hundred 
thirty-six patients with AC cell scores of 2 to 3 (10 to 49 cells 
per high-powered field) were randomized 1:1 to receive 
either drug qid for 14 days. Of the 136 patients, 127 com-
pleted the trial and were included in the efficacy analyses. 
Day 3/4 Day 8 Day 15 Day 29
Visit
Placebo (N = 220)
Difluprednate bid (N = 111)























Figure 2 Phase 3 postoperative trial: Percent of subjects with clinical response 
(anterior chamber cell count 5 and flare grade 0).Clinical Ophthalmology 2009:3 386
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The primary endpoint was change in AC cell score from 
baseline to day 14. AC flare and ocular signs and symptoms 
were also evaluated.
At day 14 improvement in AC cell scores were 
comparable between both treatments, corroborating the 
study’s noninferiority hypothesis. However, difluprednate 
produced a substantially more rapid improvement: By day 7 
more patients in the difluprednate group had AC cell scores 
of 1 or lower (P = 0.0298) (Figure 3). Similar findings were 
noted when examining secondary efficacy measures such as 
AC flare score (P  0.05) and total sign score (P = 0.0355). 
The incidence of elevated IOP was equal between the two 
groups, and resolved with or without medical treatment. None 
of the patients in the difluprednate arm withdrew from the 
study due to symptom aggravation, compared to 3 patients 
in the betamethasone group.
The safety and efficiacy of difluprednate ophthalmic emul-
sion 0.05% was further evaluated in an open-label phase 3 
trial of 19 patients with severe refractory endogenous anterior 
uveitis (50 cells per high-powered field in the anterior cham-
ber).31 These patients had not responded to previous treatment 
with betamethasone 0.1%, even when given at a frequency 
greater than the recommended qid dosing specified on its label; 
most had been dosed between 8 and 12 times per day. The 
primary efficacy measure was the change in AC cell score from 
baseline to day 14. AC flare score as well as total signs and total 
symptoms were also quantified at several time points.
Difluprednate 0.05% dosed qid demonstrated a statisti-
cally significant improvement in mean AC cell score from 
baseline [4.0 ± 0.0 (mean ± standard deviation)] to day 14 
(1.3 ± 0.8) (P  0.0001) in the 18 patients who completed 
the study (Figure 4). Significant improvements from baseline 
were also observed on day 3 (P  0.0001) and day 7 
(P  0.0001). In 13 of the 18 patients (72.2%), the AC cell 
score had improved to 1 or less by day 14, with 2 patients 
reaching 0 (Figure 5). Significant improvement from base-
line in AC flare, total sign and total symptom scores were 
noted at days 3, 7, and 14 (P  0.0002 at all measures). 
In all patients, difluprednate was well tolerated, with only 
2 participants experiencing IOP elevation, both controlled 
with topical beta blocker.
Most recently, a multicenter randomized double-masked 
trial compared the efficacy and safety of difluprednate 0.05% 
dosed qid to prednisolone acetate 1% dosed 8 times daily.32 
Ninety patients with endogenous anterior uveitis were 
randomized into 2 treatment arms to receive study medica-
tions at the above doses for 14 days, followed by 2 weeks 
of tapering at half the dose, and then 2 weeks of follow-up. 
The primary endpoint was the change in AC cell score from 
baseline.
At day 14, the mean cell grade reduction was 2.1 in 
the difluprednate arm, compared to 1.9 in the prednisolone 
acetate group, confirming the noninferiority of difluprednate 
qid to prednisolone 8 times daily (Figure 6). Several addi-
tional efficacy endpoints were achieved, but because this 
was a noninferiority study, the trial was not powered to 
reveal statistically significant differences between the two 
treatments. A greater proportion of patients receiving diflu-
prednate had an AC cell score of 0 (69%) than those using 
prednisolone (62%). Difluprednate also demonstrated an 
advantage in pain relief from baseline (Figure 7), a greater 
mean reduction in total symptom score, and a greater 
reduction in total sign score.
Day 0 Day 3 Day 7 Day 14
Difluprednate (n = 64)
























































Figure 4 Phase 3 open-label refractory uveitis trial.   Anterior chamber (AC) cell score 
mean change from baseline.Clinical Ophthalmology 2009:3 387
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No patients in the difluprednate arm withdrew from the 
study, while 12.5% of patients using prednisolone were 
withdrawn for lack of efficacy or adverse effects (P = 0.01). 
Three patients in the difluprednate treatment group and 2 
in the prednisolone group experienced increased IOP. The 
findings of this trial, along with the consistent numerical 
advantage of difluprednate across all endpoints, demonstrate 
its potency and efficacy in treating anterior uveitis.
Safety and tolerability
It has long been known that topical corticosteroids – 
especially strong steroids such as dexamethasone – can 
lead to an IOP increase. Ocular hypertension often occurs 
as early as 1 week after repeat dosing,33 an effect that 
can be much more pronounced in glaucomatous eyes.34 
IOP elevation over long periods is associated with optic 
nerve damage, leading to visual field defects and possible 
reduction in acuity. Other well documented effects of 
topical steroids include formation of posterior subcap-
sular cataracts and a predisposition to secondary ocular 
infections.
Extensive clinical testing has demonstrated that dif-
luprednate 0.05% emulsion causes an elevation in IOP 
in a small minority of patients. This increase resolved in 
all patients after stopping the medication or with topical 
pressure-lowering drops. Compared with betamethasone 
dosed at equal frequency, the incidence of IOP elevation was 
essentially equal between the two groups,27,28,30 indicating an 
acceptable safety level.
Benzalkonium chloride (BAK) is a quaternary ammo-
nium detergent35,36 used as a preservative in many ophthal-
mic products. BAK is known to break down cell walls by 
emulsifying membrane lipids,37 which disrupts the tear film 
causing immunoallergic reactions,38 and creates direct toxic-
ity to corneal and conjunctival epithelial cells. Difluprednate 
ophthalmic emulsion does not contain BAK, and instead uses 
sorbic acid as a preservative. Sorbic acid causes little damage 
and irritation to the ocular surface and is recommended for 
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Figure 5 Phase 3 open-label refractory uveitis trial. Percent of patients with anterior 
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Figure 6 Sirion phase 3 uveitis trial: anterior chamber (AC) cell score change over time.Clinical Ophthalmology 2009:3 388
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Data from phase 1 trials of single- and repeated-dose 
difluprednate show that ocular adverse events were mild 
and transient. Safety data from other studies indicate diflu-
prednate is well tolerated following ocular surgery and in 
the treatment of anterior uveitis.
Role in clinical practice
Patient expectations of surgical results and postoperative 
comfort have advanced with evolving surgical techniques 
and instrumentation. Despite this, no strong steroids have 
been approved by the FDA for the treatment of ocular 
inflammation since 1973. Technological improvments 
in pharmaceutical development now permit the creation 
of potent topical steroids with better bioavailability and 
rapid local metabolism, both of which minimize systemic 
exposure. Although weaker steroids and nonsteroidal anti-
inflammatory drugs may have a better safety profile, many 
patients will require the strongest available steroid to control 
their inflammation.
In the United States, postsurgical inflammation is treated 
prophylactically with prednisolone acetate; in other countries, 
betamethasone sodium phosphate is the standard of care. 
If left untreated, chronic inflammation can lead to further 
complications, such as pain and discomfort, cystoid macular 
edema, elevated IOP, synechiae, or keratopathy.40 Gluco-
corticoid gene activation assays have shown betamethasone 
to be intrinsically stronger than prednisolone,41 making 
betamethasone a reference drug when evaluating new 
corticosteroids for the treatment of ocular inflammation.42
In an animal model, difluprednate was found to have 
higher anti-inflammatory activity than betamethasone.23 
Clinical trials have shown that difluprednate is at least com-
parable to betamethasone in treating postoperative inflam-
mation.28 Further, unlike current-generation topical steroids, 
difluprednate is the first topical steroid indicated for the 
treatment of both postoperative inflammation and pain.
Difluprednate has also shown promising results in the 
treatment of anterior uveitis. Uveitis is the third leading 
cause of blindness in the United States, and is estimated 
to be responsible for 30,000 new cases of legal blindness 
each year.43 Uveitis may cause up to 15% of all cases of 
blindness.44
In patients with moderate anterior uveitis, diflupred-
nate yielded a significantly faster improvement than 
betamethasone, suggesting that it has a quicker and more 
potent anti-inflammatory effect.30 Difluprednate has also been 
shown to reduce inflammation in cases of severe recalcitrant 
uveitis that had failed to respond to previous betamethasone 
therapy,31 and has also produced similar anti-inflammatory 
results compared with prednisolone dosed at twice the 
frequency.32
The potency and limited systemic absorption of diflu-
prednate make it an attractive option when treating chronic 
diseases such as uveitis. In March 2009, the FDA accepted 
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Figure 7 Sirion phase 3 uveitis trial: pain score – mean change from baseline.Clinical Ophthalmology 2009:3 389
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for review a New Drug Application for difluprednate to treat 
endogenous anterior uveitis filed by Sirion Therapeutics.
Although currently approved for qid dosing, data analysis 
revealed that difluprednate bid treated postoperative inflam-
mation and discomfort effectively, even outperforming the 
qid group at some time points. From the patient’s perspec-
tive, less frequent dosing may lead to better compliance.45 
For the physician, twice-daily dosing allows flexibility when 
creating therapeutic regimens. The lower dosing reduces the 
risks of steroid exposure and permits the confident creation 
of patient-specific drop schedules, taking into account past 
medical and ocular histories, such as glaucoma.
In summary, difluprednate 0.05% ophthalmic emulsion is 
a potent new topical steroid that exhibits enhanced penetra-
tion, better bioavailability, rapid local metabolism, and strong 
efficacy with low incidence of adverse effects. It is the first 
strong ophthalmic steroid to be developed in over 30 years, 
and is effective in treating both postoperative inflammation 
and anterior uveitis.
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